Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Prescription Drugs

PUBLISHER: Grand View Research | PRODUCT CODE: 1771589

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1771589

Vyvgart (Efgartigimod) Market Size, Share & Trends Analysis Report By Indication (Generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)), By Route of Administration, By Region, And Segment Forecasts, 2025 - 2030

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Vyvgart (Efgartigimod) Market Growth & Trends:

The global Vyvgart (Efgartigimod) market size is anticipated to reach USD 5.50 billion by 2030 and is projected to grow at a CAGR of 13.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market for Vyvgart (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) antagonist developed by argenx SE, is rapidly evolving as its therapeutic footprint expands across multiple autoimmune indications. Initially approved for generalized myasthenia gravis (gMG), Vyvgart has since entered the treatment landscapes for Primary Immune Thrombocytopenia (ITP) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), with ongoing exploration into additional FcRn-related immune disorders.

Vyvgart's clinical value lies in its unique mechanism of action that reduces pathogenic IgG autoantibodies by inhibiting the FcRn recycling pathway. This targeted approach allows for selective immunomodulation without broadly suppressing the immune system, offering a favorable safety profile. The treatment has demonstrated robust efficacy in chronic, antibody-driven conditions like gMG and CIDP, with growing evidence supporting its use across other autoimmune indications.

While adult patients represent the largest treated population, especially in well-established indications such as gMG, the therapeutic potential for pediatric use is gaining momentum, particularly in chronic autoimmune neuropathies and hematologic disorders. Early intervention in younger patients could offer long-term benefits by curbing disease progression and reducing reliance on broad-spectrum immunosuppressants.

Specialty pharmacies are at the forefront of Vyvgart's distribution model, particularly due to the drug's infusion-based and subcutaneous formulations, which require precise coordination and patient support. Hospital pharmacies continue to be key partners in managing induction and complex cases, especially for newly diagnosed or severely affected patients. Increasingly, specialty distribution channels are enhancing access and adherence through personalized care programs, infusion scheduling, and remote patient engagement.

In April 2025, the FDA approved a prefilled syringe formulation of VYVGART Hytrulo for self-administration in patients with gMG and CIDP. This enables subcutaneous delivery in under 30 seconds, significantly improving treatment flexibility and adherence.

Also in April 2025, the EMA's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of VYVGART subcutaneous injection for CIDP in Europe, setting the stage for the first targeted CIDP therapy approval in the region in over three decades.

In November 2024, VYVGART Hytrulo received regulatory approval in China for treating CIDP, following strong results from the ADHERE trial. This further expanded its global footprint and solidified Argenx's position in neuromuscular markets.

As demand grows globally, ensuring consistent product availability remains a strategic priority for argenx. Investments in supply chain scalability and patient-centered digital platforms are reinforcing treatment continuity and empowering both providers and patients. These tools are especially critical in managing long-term, relapsing autoimmune conditions, where seamless care transitions and proactive disease monitoring can significantly impact outcomes.

The success of Vyvgart underscores a broader paradigm shift toward precision immunotherapies that modulate specific disease pathways with durable, targeted effects. As awareness and diagnostic capabilities for autoimmune diseases continue to improve, Vyvgart is poised to remain a leading option in the FcRn inhibition class, driving better outcomes and reshaping the standard of care across a range of debilitating immune-mediated disorders.

Vyvgart (Efgartigimod) Market Report Highlights:

  • Based on indication, Generalized Myasthenia Gravis (gMG) remained the leading indication in the Vyvgart (Efgartigimod) market in 2024, accounting for the largest share due to the high prevalence of antibody-positive patients and the drug's targeted mechanism of action through FcRn inhibition. Strong clinical outcomes, favorable safety profile, and updates to treatment guidelines have accelerated adoption across major markets.
  • Based on route of administration, Intravenous (IV) Infusion dominated the route of administration segment in 2024, primarily due to its early commercial availability and widespread adoption in hospital settings for induction therapy. However, the market is witnessing a rapid shift towards subcutaneous formulations, particularly the recently approved prefilled syringe, which offers self-administration and greater patient convenience.
  • North America led the Vyvgart market in 2024, supported by high diagnosis and treatment rates of autoimmune diseases, favorable reimbursement policies, and a robust specialty pharmacy infrastructure. The region also benefits from increasing clinical trial activity and early adoption of innovative immunotherapies.
  • Argenx SE continued to lead the Vyvgart (Efgartigimod) market globally, leveraging its robust R&D pipeline, expanding international approvals, and strategic partnerships with regional players like Zai Lab in China. The company's focus on supply chain resilience, patient assistance programs, and platform-based development supports its long-term growth across multiple indications and geographies.
Show more
Product Code: GVR-4-68040-618-7

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Vyvgart (Efgartigimod) Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
  • 3.4. Pipeline Analysis
  • 3.5. Patent Expiry Analysis
  • 3.6. Pricing Analysis

Chapter 4. Vyvgart (Efgartigimod) Market: Indication Business Analysis

  • 4.1. Indication Market Share, 2024 & 2030
  • 4.2. Indication Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 4.4. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    • 4.4.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, 2018 - 2030 (USD Million)
  • 4.5. Generalized Myasthenia Gravis (gMG)
    • 4.5.1. Generalized Myasthenia Gravis (gMG) Market, 2018 - 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Vyvgart (Efgartigimod) Market: Route of Administration Business Analysis

  • 5.1. Route of Administration Market Share, 2024 & 2030
  • 5.2. Route of Administration Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 5.4. Intravenous (IV) Infusion
    • 5.4.1. Intravenous (IV) Infusion Market, 2018 - 2030 (USD Million)
  • 5.5. Subcutaneous (SC) Injection
    • 5.5.1. Subcutaneous (SC) Injection Market, 2018 - 2030 (USD Million)
  • 5.6. Prefilled Syringes
    • 5.6.1. Prefilled Syringe Market, 2018 - 2030 (USD Million)

Chapter 6. Vyvgart (Efgartigimod) Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. Uk Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Argenx SE
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives

Chapter 8. Conclusion

Show more
Product Code: GVR-4-68040-618-7

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global Vyvgart (Efgartigimod) market, by region, 2018 - 2030 (USD Million)
  • Table 4. Global Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 5. Global Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 6. North America Vyvgart (Efgartigimod) market, by country, 2018 - 2030 (USD Million)
  • Table 7. North America Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 8. North America Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 9. U.S. Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 10. U.S. Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 11. Canada Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 12. Canada Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 13. Mexico Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 14. Mexico Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 15. Europe Vyvgart (Efgartigimod) market, by country, 2018 - 2030 (USD Million)
  • Table 16. Europe Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 17. Europe Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 18. UK Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 19. UK Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 20. Germany Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 21. Germany Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 22. France Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 23. France Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 24. Italy Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 25. Italy Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 26. Spain Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 27. Spain Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 28. Norway Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 29. Norway Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 30. Denmark Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 31. Denmark Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 32. Sweden Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 33. Sweden Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 34. Asia Pacific Vyvgart (Efgartigimod) market, by country, 2018 - 2030 (USD Million)
  • Table 35. Asia Pacific Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 36. Asia Pacific Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 37. Japan Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 38. Japan Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 39. China Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 40. China Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 41. India Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 42. India Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 43. Australia Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 44. Australia Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 45. South Korea Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 46. South Korea Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 47. Thailand Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 48. Thailand Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 49. Latin America Vyvgart (Efgartigimod) market, by country, 2018 - 2030 (USD Million)
  • Table 50. Latin America Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 51. Latin America Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 52. Brazil Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 53. Brazil Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 54. Argentina Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 55. Argentina Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 56. Middle East & Africa Vyvgart (Efgartigimod) market, by country, 2018 - 2030 (USD Million)
  • Table 57. Middle East & Africa Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 58. Middle East & Africa Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 59. South Africa Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 60. South Africa Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 61. Saudi Arabia Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 62. Saudi Arabia Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 63. UAE Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 64. UAE Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 65. Kuwait Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 66. Kuwait Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Vyvgart (Efgartigimod) market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Indication and route of administration outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Vyvgart (Efgartigimod) market dynamics
  • Fig. 12 Vyvgart (Efgartigimod) market: Porter's five forces analysis
  • Fig. 13 Vyvgart (Efgartigimod) market: PESTLE analysis
  • Fig. 14 Indication market, 2018 - 2030 (USD Million)
  • Fig. 15 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market, 2018 - 2030 (USD Million)
  • Fig. 16 Generalized Myasthenia Gravis (gMG) market, 2018 - 2030 (USD Million)
  • Fig. 17 Others market, 2018 - 2030 (USD Million)
  • Fig. 18 Route of Administration market, 2018 - 2030 (USD Million)
  • Fig. 19 Intravenous (IV) Infusion market, 2018 - 2030 (USD Million)
  • Fig. 20 Subcutaneous (SC) Injection market, 2018 - 2030 (USD Million)
  • Fig. 21 Prefilled Syringe market, 2018 - 2030 (USD Million)
  • Fig. 22 Vyvgart (Efgartigimod) market revenue, by region
  • Fig. 23 Regional marketplace: Key takeaways
  • Fig. 24 North America Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. country dynamics
  • Fig. 26 U.S. Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 27 Canada country dynamics
  • Fig. 28 Canada Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 29 Mexico country dynamics
  • Fig. 30 Mexico Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 31 Europe Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 32 UK country dynamics
  • Fig. 33 UK Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 34 Germany country dynamics
  • Fig. 35 Germany Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 36 France country dynamics
  • Fig. 37 France Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 38 Italy country dynamics
  • Fig. 39 Italy Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 40 Spain country dynamics
  • Fig. 41 Spain Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 42 Norway country dynamics
  • Fig. 43 Norway Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 44 Sweden country dynamics
  • Fig. 45 Sweden Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 46 Denmark country dynamics
  • Fig. 47 Denmark Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 48 Asia Pacific Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 49 Japan country dynamics
  • Fig. 50 Japan Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 51 China country dynamics
  • Fig. 52 China Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 53 India country dynamics
  • Fig. 54 India Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 55 Australia country dynamics
  • Fig. 56 Australia Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 57 South Korea country dynamics
  • Fig. 58 South Korea Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 59 Thailand country dynamics
  • Fig. 60 Thailand Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 61 Latin America Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 62 Brazil country dynamics
  • Fig. 63 Brazil Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 64 Argentina country dynamics
  • Fig. 65 Argentina Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 66 MEA Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 67 South Africa country dynamics
  • Fig. 68 South Africa Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 69 Saudi Arabia country dynamics
  • Fig. 70 Saudi Arabia Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 71 UAE country dynamics
  • Fig. 72 UAE Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 73 Kuwait country dynamics
  • Fig. 74 Kuwait Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 75 Company categorization
  • Fig. 76 Company market position analysis
  • Fig. 77 Strategic framework
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!